“Clinical Response and Safety of Alternating Daily Dosage of Crizotinib due to Side Effects in Advanced NSCLC patient harboring ROS1-rearrangement: A Case Report” (2023) Jurnal Respirologi Indonesia, 43(2), pp. 111–115. doi:10.36497/jri.v43i2.201.